Passage Bio, Inc. announced that in conjunction with the headcount reduction, Eliseo O. Salinas, M.D., MSc, chief research and development officer, will be retiring and departing from the Company effective March 18, 2022. Mark Forman, M.D., Ph.D., chief medical officer, will continue to lead execution of the ongoing clinical trials.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.175 USD | -1.26% | -4.51% | +15.35% |
05-15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
05-14 | Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.35% | 73.35M | |
+7.84% | 114B | |
+9.26% | 104B | |
+1.19% | 22.57B | |
-12.46% | 22.5B | |
-10.67% | 17.95B | |
-41.90% | 16.48B | |
-15.38% | 15.82B | |
+2.69% | 13.55B | |
+24.87% | 10.99B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio, Inc. Announces Executive Changes, Effective March 18, 2022